Amitriptyline versus Trifluoperazine for functional dyspepsia
Official title: Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia
Run by Dhaka Medical College · NCT07008235 · Data updated 2026-11-12
This trial will test whether adding low‑dose amitriptyline or trifluoperazine to standard treatment helps adults with functional dyspepsia feel better over 8 weeks.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Dhaka Medical College Academic / other |
| Locations | 1 site (Dhaka) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | May 7, 2026 |
| Trial ID | NCT07008235 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with symptoms meeting Rome IV criteria for functional dyspepsia who can give informed consent and attend study visits are ideal candidates.
✕Probably not a fit
Patients with structural upper GI disease, major medical or psychiatric comorbidities, current use of antidepressants or antipsychotics, prior hypersensitivity to the study drugs, or needing contraindicated co‑medications are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with functional dyspepsia will be assigned to one of three groups: amitriptyline 10 mg at night plus standard first‑line therapy, trifluoperazine 1 mg twice daily plus standard therapy, or standard therapy alone for 8 weeks. Symptom changes and patient‑reported adverse events will be recorded to compare benefit and safety between the groups. After the 8‑week treatment period, all groups will be followed according to the protocol described by the investigators. The trial focuses on symptomatic improvement using established dyspepsia criteria and routine safety monitoring.
Why it matters
Potential benefit: If successful, adding one of these low‑dose neuromodulators could reduce dyspepsia symptoms and improve daily comfort for patients.
How similar studies have gone: Low‑dose tricyclics such as amitriptyline have shown benefit in some functional GI disorder studies, while trifluoperazine is less well studied for functional dyspepsia.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or more * Patients with symptoms of dyspepsia for duration consisted with ROME IV criteria * Patients who are willing to sign informed written consent Exclusion Criteria: * Structural lesion in Upper GI endoscopy and/or positive CLO test * Patients scoring 1 or 2 on the 5-point Likert scale for all four dyspepsia symptoms * History of malignancy, significant liver and biliary tract disease, hypertension, diabetes mellitus, chronic kidney disease, thyroid disorder, major psychiatric disorders * Previous history of gastrointestinal surgery * Patients those have to take any drug for other medical condition that may cause dyspepsia, can interfere or whose co-prescription is contraindicated with amitriptyline or trifluoperazine * Any patient with ongoing treatment with antidepressants or antipsychotics * Any history of hypersensitivity, adverse effect, or ineffectiveness with amitriptyline or trifluoperazine * Patients for whom Amitriptyline and Trifluoperazine are contraindicated * Elderly patients\> 60 years * Pregnancy and breastfeeding
Where it's running
-
Dhaka Medical College
Dhaka, Bangladesh Recruiting
Study contacts
- Study coordinator: Md. Moktadirul Hoque Shuvo, MBBS
- Email: kdshuvo1430@gmail.com
- Phone: +8801788450963
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-FODMAP Diet vs Standard Dietary Advice for Functional Dyspepsia
This study tests whether a low-FODMAP diet helps adults with functional dyspepsia compared with standard dietary advice.
-
Pain Reprocessing Therapy for Functional Dyspepsia
A small pilot test to see if a psychological therapy that uses exposure techniques can lessen digestive symptoms and help daily functioning in people with functional dyspepsia.
-
Identifying Signatures of Gut Interoception in Functional Dyspepsia and Anorexia Nervosa
This study tests how the gut-brain connection works in people with functional dyspepsia or anorexia nervosa using brain imaging.
-
Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers
Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Prevalence of Functional Dyspepsia in a Rural Community in Bangladesh
This study tests how common functional dyspepsia is in a rural Bangladeshi community among adults who live there.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.